STK
Columbia Seligman Premium Technology Growth FundSTK
STK
About: Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
3.83% more ownership
Funds ownership: 15.21% [Q2] → 19.04% (+3.83%) [Q3]
0% more funds holding
Funds holding: 60 [Q2] → 60 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
10% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 21
9% less capital invested
Capital invested by funds: $83.8M [Q2] → $76.6M (-$7.23M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for STK.
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
Columbia Seligman Premium Technology Growth Fund Announces a Special Fourth Quarter Distribution
BOSTON--(BUSINESS WIRE)--Today, Columbia Seligman Premium Technology Growth Fund, Inc. (NYSE: STK) (the Fund) declared a special fourth quarter distribution, beyond its typical quarterly managed distribution policy, in the amount of $3.2669 per share. A federal excise tax of 4% applies to funds that do not distribute substantially all of their annual income (including net gains) before the end of their fiscal year. The Fund's income for the current fiscal year exceeds the amounts previously dis.
Positive
Seeking Alpha
4 weeks ago
5 Best CEFs This Month For 8.5% Yield (November 2024)
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer "excess" discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.
Positive
Seeking Alpha
1 month ago
STK: A Technology Equity Fund With Call Overwrite, A 5.5% Yield And Solid Growth
STK is a closed-end fund that primarily invests in high-growth technology stocks and utilizes call overwrite to reduce volatility and generate income. Besides high growth potential, currently, the fund yields nearly 5.5%, making it a good investment for income investors. Besides moderate income, the past growth record has been excellent. We would rate the fund as a 'hold' for existing owners and a 'buy' for new investors as a diversification in the technology space. However, the new buyers should use dollar-cost-averaging to avoid the risk of buying near the top.
Neutral
Business Wire
1 month ago
Columbia Seligman Premium Technology Growth Fund Announces a Fourth Quarter Distribution: 9.25% Annual Rate for IPO Investors
BOSTON--(BUSINESS WIRE)--Today, Columbia Seligman Premium Technology Growth Fund, Inc. (NYSE: STK) (the Fund) declared a fourth-quarter distribution, pursuant to its managed distribution policy, in the amount of $0.4625 per share, which is equal to a quarterly rate of 2.3125% (9.25% annualized) of the $20.00 offering price in the Fund's initial public offering in November 2009. The fourth-quarter distribution of $0.4625 per share is equal to a quarterly rate of 1.4131% (5.65% annualized) of the.
Positive
Seeking Alpha
1 month ago
STK: Unlock Higher Income Even If Tech Growth Slows
Columbia Seligman Premium Technology Growth Fund offers a balance between growth and income, leveraging an option strategy to generate a 6.5% dividend yield. STK's diverse tech holdings focus on downside volatility mitigation, with semiconductors and software sectors comprising nearly half of its portfolio. Despite potential vulnerabilities, STK's price trading at a discount to NAV and consistent dividend history make it an attractive buy for income-focused investors.
Positive
Forbes
2 months ago
Forget Tech Volatility: ‘Go Global' With This Steady 8.1% Payer
Closed-end funds (CEFs), with an average yield of around 8%, are terrific for just about any investor—especially those looking to their portfolios to help pay the bills.
Positive
Seeking Alpha
4 months ago
5 Best CEFs This Month For Nearly 9% Yield (July 2024)
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer “excess” discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.
Positive
Forbes
5 months ago
These 8%+ Dividends Are Beating Hedge Funds At Their Own Game
Hedge funds have a big problem: They can't beat the market anymore.
Neutral
Business Wire
5 months ago
Columbia Seligman Premium Technology Growth Fund, Inc. Holds 14th Annual Meeting of Stockholders
MINNEAPOLIS--(BUSINESS WIRE)--Columbia Seligman Premium Technology Growth Fund, Inc. (the “Fund”) (NYSE: STK) today held its 14th Annual Meeting of Stockholders (the “Meeting”) in Minneapolis, Minnesota. Stockholders voted in favor of the recommendations of the Fund's Board of Directors (the “Board”) on each of two proposals at the Meeting. Specifically, Stockholders re-elected Directors Kathleen Blatz, Pamela G. Carlton and George S. Batejan and elected David M. Moffett, each for a term that w.
Neutral
Business Wire
5 months ago
PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology and immunology, today announced completion of enrollment for two clinical trials evaluating its ropeginterferon alfa-2b-njft (BESREMi®). The Phase 2b EXCEED-ET trial (NCT05482971), which is evaluating the effectiv.
Charts implemented using Lightweight Charts™